We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global POC Molecular Diagnostics Market Driven by Increasing Demand for Rapid and Accurate Testing

By LabMedica International staff writers
Posted on 20 Jun 2023

The demand for rapid and accurate diagnostic techniques has witnessed a surge, resulting in increased demand for point of care (POC) molecular diagnostics due to its numerous benefits. More...

These include quick turnaround times, portability, and the capacity to deliver results in the patient's immediate surroundings or in settings with limited resources. There is tremendous potential in POC molecular diagnostics to transform healthcare delivery by offering quick and accurate diagnosis at the point of need. Thus, significant growth and advancements in the global POC molecular diagnostics market are anticipated in the coming years. The global POC molecular diagnostics market is projected to register a compound annual growth rate (CAGR) of 10.6% from about USD 2 billion in 2023 to USD 3.4 billion in 2028. The market growth will be primarily driven by the rising occurrence of infectious diseases and cancer, increasing emphasis on decentralized diagnostics, surge in R&D funding, growing awareness about early infection detection, and high utilization of POC diagnostic tests.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a market research firm.

The development of more compact and user-friendly devices is likely in the POC molecular diagnostics market. These devices will have the ability to detect a wide range of diseases, including infectious diseases, genetic disorders, and cancer, with high sensitivity and specificity. These advancements will enable healthcare providers to make timely and informed treatment decisions, leading to improved patient outcomes. Additionally, the integration of artificial intelligence and machine learning algorithms into POC molecular diagnostics platforms will enhance diagnostic accuracy and interpretation of results. The market growth will also be fueled by the increasing prevalence of infectious diseases, the need for decentralized testing, and a growing focus on personalized medicine.

Based on products & services, the assays & kits segment held the largest share of the POC molecular diagnostics market in 2022. Assays & kits are widely utilized in various POC settings such as hospital critical care units, physicians' offices, outpatient clinics, home care settings, and long-term care settings. The continuous demand and recurring purchases of assays & kits are anticipated to fuel the segment’s growth and consequently, that of the POC molecular diagnostics market. On the basis of technology, the RT-PCR segment accounted for the largest share of the POC molecular diagnostics market in 2022. This can be attributed to the fact that RT-PCR is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and quick turnaround time (4 to 6 hours).

Based on end user, the physicians' offices segment held the largest share of the POC molecular diagnostics market in 2022. POC molecular assay & kits and systems are widely utilized in these settings because they offer rapid results within 30 minutes. This aids in immediate diagnosis, enabling physicians to swiftly diagnose or monitor a patient's condition. Based on application, the respiratory diseases segment had the largest share in the POC molecular diagnostics market in 2022 due to the rising prevalence of infectious diseases and the increasing demand for early detection and diagnosis of these diseases. This is particularly relevant in emerging nations, where the need to tackle the challenges of infectious diseases through timely and accurate molecular diagnostics is more prominent.

Geographically, North America dominated the global POC molecular diagnostics market in 2022 with the largest share, which can be attributed to the highly advanced healthcare system in the region and the high burden of infectious diseases and cancers on regional healthcare systems. Recent years have seen a marked increase in healthcare spending across North America. National health spending is projected to grow at an average annual rate of 5.4% from 2019 to 2028, reaching an astounding USD 6.2 trillion by 2028, as per the Centers for Medicare & Medicaid Services. This surge in healthcare expenditure is a crucial driver for the growth of the North American POC molecular diagnostics market. The presence of a well-developed healthcare infrastructure and the growing adoption of advanced technologies for infectious disease testing will further support the growth of the POC molecular diagnostics market in North America.

Related Links:
MarketsandMarkets 


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Serological Pipet Controller
PIPETBOY GENIUS
New
Uric Acid Meter
PA-16
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: PhD researcher Olivia Moscatelli and Associate Professor Jason Tye-Din with the highly sensitive technology used to detect the critical IL-2 signal (Photo courtesy of WEHI)

Groundbreaking Blood Test Detects Celiac Disease in Patients Without Gluten Exposure

Getting a reliable diagnosis for coeliac disease has long required patients to endure weeks of consuming gluten—a painful process for many already following gluten-free diets. Now, a groundbreaking blood... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The LIAISON PLEX® Gram-Positive Blood Culture Assay runs on the on the LIAISON PLEX instrument (Photo courtesy of Diasorin)

Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection

Each year, around 250,000 individuals in the US are diagnosed with bloodstream infections (BSIs). Sepsis caused by these infections carries a mortality rate ranging from 16% to 40%, and any delay in administering... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.